{
  "symbol": "AMGN",
  "year": 2023,
  "period": "Q1",
  "curated_text": "Symbol: AMGN. Year: 2023. Period: Q1. ReportType: Q10. Section: Competition and Market Position. This section discusses competitors, market dynamics, and regulatory landscape.  Competitors mentioned: Litigation Amgen Inc., Sandoz Inc., the U.S. District Court, Lek Pharmaceuticals, Novartis Pharmaceutical Productions, Novartis AG, the New Jersey District Court, Sandoz, District Court, Amgen, the U.S. Court of Appeals, the Third Circuit, Regeneron Pharmaceuticals, Inc., Regeneron, CVS, U.S. Tax Litigation, Related Matters Amgen Inc. & Subsidiaries, IRS, Company, the U.S. Tax Court, Shareholder Derivative Litigation, ChemoCentryx, FTC Litigation, the Horizon Therapeutics plc Acquisition, FTC, ANALYSIS OF FINANCIAL CONDITION, MD&A, SEC, EPS. Context excerpt: petition and Innovation Act (BPCIA) Litigation Amgen Inc. et al. v. Sandoz Inc., et al. On August 23, 2023, the U.S. District Court for the District of New Jersey (New Jersey District Court) entered a stipulation and order dismissing without prejudice Sandoz GmbH, Lek Pharmaceuticals d.d., Novartis Pharmaceutical Productions d.o.o. and Novartis AG (collectively \u201cForeign Defendants\u201d) from the action. Pursuant to the stipulation entered by the New Jersey District Court, the Foreign Defendants agreed to be bound by any judgment order or decision in the matter (including appeals) as if the Foreign Defendants were named as defendants and parties to the judgment order or decision. Sandoz Inc. (Sandoz) is now the sole named defendant in the action. On October 30, 2023, the New Jersey District Court commenced a hearing on Amgen\u2019s motion for a preliminary injunction to prohibit Sandoz from engaging in the commercial manufacture, use, offer for sell or sale within the United States, or importati",
  "competition_summary": [
    {
      "competitor": "Litigation Amgen Inc.",
      "mentions": 1,
      "context": "petition and Innovation Act (BPCIA) Litigation Amgen Inc. et al. v. Sandoz Inc., et al. On August 23, 2023, the U.S. District Court for the District of New Jersey (New Jersey District Court) entered a stipulation and order dismissing without prejudice Sandoz GmbH, Lek Pharmaceuticals d.d., Novartis Pharmaceutical Productions d.o.o. and Novartis AG (collectively \u201cForeign Defendants\u201d) from the action. Pursuant to the stipulation entered by the New Jersey District Court, the Foreign Defendants agre"
    },
    {
      "competitor": "Sandoz Inc.",
      "mentions": 2,
      "context": "petition and Innovation Act (BPCIA) Litigation Amgen Inc. et al. v. Sandoz Inc., et al. On August 23, 2023, the U.S. District Court for the District of New Jersey (New Jersey District Court) entered a stipulation and order dismissing without prejudice Sandoz GmbH, Lek Pharmaceuticals d.d., Novartis Pharmaceutical Productions d.o.o. and Novartis AG (collectively \u201cForeign Defendants\u201d) from the action. Pursuant to the stipulation entered by the New Jersey District Court, the Foreign Defendants agre"
    },
    {
      "competitor": "the U.S. District Court",
      "mentions": 2,
      "context": "petition and Innovation Act (BPCIA) Litigation Amgen Inc. et al. v. Sandoz Inc., et al. On August 23, 2023, the U.S. District Court for the District of New Jersey (New Jersey District Court) entered a stipulation and order dismissing without prejudice Sandoz GmbH, Lek Pharmaceuticals d.d., Novartis Pharmaceutical Productions d.o.o. and Novartis AG (collectively \u201cForeign Defendants\u201d) from the action. Pursuant to the stipulation entered by the New Jersey District Court, the Foreign Defendants agre"
    },
    {
      "competitor": "Lek Pharmaceuticals",
      "mentions": 1,
      "context": "petition and Innovation Act (BPCIA) Litigation Amgen Inc. et al. v. Sandoz Inc., et al. On August 23, 2023, the U.S. District Court for the District of New Jersey (New Jersey District Court) entered a stipulation and order dismissing without prejudice Sandoz GmbH, Lek Pharmaceuticals d.d., Novartis Pharmaceutical Productions d.o.o. and Novartis AG (collectively \u201cForeign Defendants\u201d) from the action. Pursuant to the stipulation entered by the New Jersey District Court, the Foreign Defendants agre"
    },
    {
      "competitor": "Novartis Pharmaceutical Productions",
      "mentions": 1,
      "context": "petition and Innovation Act (BPCIA) Litigation Amgen Inc. et al. v. Sandoz Inc., et al. On August 23, 2023, the U.S. District Court for the District of New Jersey (New Jersey District Court) entered a stipulation and order dismissing without prejudice Sandoz GmbH, Lek Pharmaceuticals d.d., Novartis Pharmaceutical Productions d.o.o. and Novartis AG (collectively \u201cForeign Defendants\u201d) from the action. Pursuant to the stipulation entered by the New Jersey District Court, the Foreign Defendants agre"
    },
    {
      "competitor": "Novartis AG",
      "mentions": 1,
      "context": "petition and Innovation Act (BPCIA) Litigation Amgen Inc. et al. v. Sandoz Inc., et al. On August 23, 2023, the U.S. District Court for the District of New Jersey (New Jersey District Court) entered a stipulation and order dismissing without prejudice Sandoz GmbH, Lek Pharmaceuticals d.d., Novartis Pharmaceutical Productions d.o.o. and Novartis AG (collectively \u201cForeign Defendants\u201d) from the action. Pursuant to the stipulation entered by the New Jersey District Court, the Foreign Defendants agre"
    },
    {
      "competitor": "the New Jersey District Court",
      "mentions": 1,
      "context": "petition and Innovation Act (BPCIA) Litigation Amgen Inc. et al. v. Sandoz Inc., et al. On August 23, 2023, the U.S. District Court for the District of New Jersey (New Jersey District Court) entered a stipulation and order dismissing without prejudice Sandoz GmbH, Lek Pharmaceuticals d.d., Novartis Pharmaceutical Productions d.o.o. and Novartis AG (collectively \u201cForeign Defendants\u201d) from the action. Pursuant to the stipulation entered by the New Jersey District Court, the Foreign Defendants agre"
    },
    {
      "competitor": "Sandoz",
      "mentions": 1,
      "context": "petition and Innovation Act (BPCIA) Litigation Amgen Inc. et al. v. Sandoz Inc., et al. On August 23, 2023, the U.S. District Court for the District of New Jersey (New Jersey District Court) entered a stipulation and order dismissing without prejudice Sandoz GmbH, Lek Pharmaceuticals d.d., Novartis Pharmaceutical Productions d.o.o. and Novartis AG (collectively \u201cForeign Defendants\u201d) from the action. Pursuant to the stipulation entered by the New Jersey District Court, the Foreign Defendants agre"
    },
    {
      "competitor": "District Court",
      "mentions": 1,
      "context": "petition and Innovation Act (BPCIA) Litigation Amgen Inc. et al. v. Sandoz Inc., et al. On August 23, 2023, the U.S. District Court for the District of New Jersey (New Jersey District Court) entered a stipulation and order dismissing without prejudice Sandoz GmbH, Lek Pharmaceuticals d.d., Novartis Pharmaceutical Productions d.o.o. and Novartis AG (collectively \u201cForeign Defendants\u201d) from the action. Pursuant to the stipulation entered by the New Jersey District Court, the Foreign Defendants agre"
    },
    {
      "competitor": "Amgen",
      "mentions": 7,
      "context": "petition and Innovation Act (BPCIA) Litigation Amgen Inc. et al. v. Sandoz Inc., et al. On August 23, 2023, the U.S. District Court for the District of New Jersey (New Jersey District Court) entered a stipulation and order dismissing without prejudice Sandoz GmbH, Lek Pharmaceuticals d.d., Novartis Pharmaceutical Productions d.o.o. and Novartis AG (collectively \u201cForeign Defendants\u201d) from the action. Pursuant to the stipulation entered by the New Jersey District Court, the Foreign Defendants agre"
    },
    {
      "competitor": "the U.S. Court of Appeals",
      "mentions": 1,
      "context": "petition and Innovation Act (BPCIA) Litigation Amgen Inc. et al. v. Sandoz Inc., et al. On August 23, 2023, the U.S. District Court for the District of New Jersey (New Jersey District Court) entered a stipulation and order dismissing without prejudice Sandoz GmbH, Lek Pharmaceuticals d.d., Novartis Pharmaceutical Productions d.o.o. and Novartis AG (collectively \u201cForeign Defendants\u201d) from the action. Pursuant to the stipulation entered by the New Jersey District Court, the Foreign Defendants agre"
    },
    {
      "competitor": "the Third Circuit",
      "mentions": 1,
      "context": "petition and Innovation Act (BPCIA) Litigation Amgen Inc. et al. v. Sandoz Inc., et al. On August 23, 2023, the U.S. District Court for the District of New Jersey (New Jersey District Court) entered a stipulation and order dismissing without prejudice Sandoz GmbH, Lek Pharmaceuticals d.d., Novartis Pharmaceutical Productions d.o.o. and Novartis AG (collectively \u201cForeign Defendants\u201d) from the action. Pursuant to the stipulation entered by the New Jersey District Court, the Foreign Defendants agre"
    },
    {
      "competitor": "Regeneron Pharmaceuticals, Inc.",
      "mentions": 1,
      "context": "petition and Innovation Act (BPCIA) Litigation Amgen Inc. et al. v. Sandoz Inc., et al. On August 23, 2023, the U.S. District Court for the District of New Jersey (New Jersey District Court) entered a stipulation and order dismissing without prejudice Sandoz GmbH, Lek Pharmaceuticals d.d., Novartis Pharmaceutical Productions d.o.o. and Novartis AG (collectively \u201cForeign Defendants\u201d) from the action. Pursuant to the stipulation entered by the New Jersey District Court, the Foreign Defendants agre"
    },
    {
      "competitor": "Regeneron",
      "mentions": 3,
      "context": "petition and Innovation Act (BPCIA) Litigation Amgen Inc. et al. v. Sandoz Inc., et al. On August 23, 2023, the U.S. District Court for the District of New Jersey (New Jersey District Court) entered a stipulation and order dismissing without prejudice Sandoz GmbH, Lek Pharmaceuticals d.d., Novartis Pharmaceutical Productions d.o.o. and Novartis AG (collectively \u201cForeign Defendants\u201d) from the action. Pursuant to the stipulation entered by the New Jersey District Court, the Foreign Defendants agre"
    },
    {
      "competitor": "CVS",
      "mentions": 1,
      "context": "petition and Innovation Act (BPCIA) Litigation Amgen Inc. et al. v. Sandoz Inc., et al. On August 23, 2023, the U.S. District Court for the District of New Jersey (New Jersey District Court) entered a stipulation and order dismissing without prejudice Sandoz GmbH, Lek Pharmaceuticals d.d., Novartis Pharmaceutical Productions d.o.o. and Novartis AG (collectively \u201cForeign Defendants\u201d) from the action. Pursuant to the stipulation entered by the New Jersey District Court, the Foreign Defendants agre"
    },
    {
      "competitor": "U.S. Tax Litigation",
      "mentions": 1,
      "context": "petition and Innovation Act (BPCIA) Litigation Amgen Inc. et al. v. Sandoz Inc., et al. On August 23, 2023, the U.S. District Court for the District of New Jersey (New Jersey District Court) entered a stipulation and order dismissing without prejudice Sandoz GmbH, Lek Pharmaceuticals d.d., Novartis Pharmaceutical Productions d.o.o. and Novartis AG (collectively \u201cForeign Defendants\u201d) from the action. Pursuant to the stipulation entered by the New Jersey District Court, the Foreign Defendants agre"
    },
    {
      "competitor": "Related Matters Amgen Inc. & Subsidiaries",
      "mentions": 1,
      "context": "petition and Innovation Act (BPCIA) Litigation Amgen Inc. et al. v. Sandoz Inc., et al. On August 23, 2023, the U.S. District Court for the District of New Jersey (New Jersey District Court) entered a stipulation and order dismissing without prejudice Sandoz GmbH, Lek Pharmaceuticals d.d., Novartis Pharmaceutical Productions d.o.o. and Novartis AG (collectively \u201cForeign Defendants\u201d) from the action. Pursuant to the stipulation entered by the New Jersey District Court, the Foreign Defendants agre"
    },
    {
      "competitor": "IRS",
      "mentions": 1,
      "context": "petition and Innovation Act (BPCIA) Litigation Amgen Inc. et al. v. Sandoz Inc., et al. On August 23, 2023, the U.S. District Court for the District of New Jersey (New Jersey District Court) entered a stipulation and order dismissing without prejudice Sandoz GmbH, Lek Pharmaceuticals d.d., Novartis Pharmaceutical Productions d.o.o. and Novartis AG (collectively \u201cForeign Defendants\u201d) from the action. Pursuant to the stipulation entered by the New Jersey District Court, the Foreign Defendants agre"
    },
    {
      "competitor": "Company",
      "mentions": 1,
      "context": "petition and Innovation Act (BPCIA) Litigation Amgen Inc. et al. v. Sandoz Inc., et al. On August 23, 2023, the U.S. District Court for the District of New Jersey (New Jersey District Court) entered a stipulation and order dismissing without prejudice Sandoz GmbH, Lek Pharmaceuticals d.d., Novartis Pharmaceutical Productions d.o.o. and Novartis AG (collectively \u201cForeign Defendants\u201d) from the action. Pursuant to the stipulation entered by the New Jersey District Court, the Foreign Defendants agre"
    },
    {
      "competitor": "the U.S. Tax Court",
      "mentions": 1,
      "context": "petition and Innovation Act (BPCIA) Litigation Amgen Inc. et al. v. Sandoz Inc., et al. On August 23, 2023, the U.S. District Court for the District of New Jersey (New Jersey District Court) entered a stipulation and order dismissing without prejudice Sandoz GmbH, Lek Pharmaceuticals d.d., Novartis Pharmaceutical Productions d.o.o. and Novartis AG (collectively \u201cForeign Defendants\u201d) from the action. Pursuant to the stipulation entered by the New Jersey District Court, the Foreign Defendants agre"
    },
    {
      "competitor": "Shareholder Derivative Litigation",
      "mentions": 1,
      "context": "petition and Innovation Act (BPCIA) Litigation Amgen Inc. et al. v. Sandoz Inc., et al. On August 23, 2023, the U.S. District Court for the District of New Jersey (New Jersey District Court) entered a stipulation and order dismissing without prejudice Sandoz GmbH, Lek Pharmaceuticals d.d., Novartis Pharmaceutical Productions d.o.o. and Novartis AG (collectively \u201cForeign Defendants\u201d) from the action. Pursuant to the stipulation entered by the New Jersey District Court, the Foreign Defendants agre"
    },
    {
      "competitor": "ChemoCentryx",
      "mentions": 2,
      "context": "petition and Innovation Act (BPCIA) Litigation Amgen Inc. et al. v. Sandoz Inc., et al. On August 23, 2023, the U.S. District Court for the District of New Jersey (New Jersey District Court) entered a stipulation and order dismissing without prejudice Sandoz GmbH, Lek Pharmaceuticals d.d., Novartis Pharmaceutical Productions d.o.o. and Novartis AG (collectively \u201cForeign Defendants\u201d) from the action. Pursuant to the stipulation entered by the New Jersey District Court, the Foreign Defendants agre"
    },
    {
      "competitor": "FTC Litigation",
      "mentions": 1,
      "context": "petition and Innovation Act (BPCIA) Litigation Amgen Inc. et al. v. Sandoz Inc., et al. On August 23, 2023, the U.S. District Court for the District of New Jersey (New Jersey District Court) entered a stipulation and order dismissing without prejudice Sandoz GmbH, Lek Pharmaceuticals d.d., Novartis Pharmaceutical Productions d.o.o. and Novartis AG (collectively \u201cForeign Defendants\u201d) from the action. Pursuant to the stipulation entered by the New Jersey District Court, the Foreign Defendants agre"
    },
    {
      "competitor": "the Horizon Therapeutics plc Acquisition",
      "mentions": 1,
      "context": "petition and Innovation Act (BPCIA) Litigation Amgen Inc. et al. v. Sandoz Inc., et al. On August 23, 2023, the U.S. District Court for the District of New Jersey (New Jersey District Court) entered a stipulation and order dismissing without prejudice Sandoz GmbH, Lek Pharmaceuticals d.d., Novartis Pharmaceutical Productions d.o.o. and Novartis AG (collectively \u201cForeign Defendants\u201d) from the action. Pursuant to the stipulation entered by the New Jersey District Court, the Foreign Defendants agre"
    },
    {
      "competitor": "FTC",
      "mentions": 2,
      "context": "petition and Innovation Act (BPCIA) Litigation Amgen Inc. et al. v. Sandoz Inc., et al. On August 23, 2023, the U.S. District Court for the District of New Jersey (New Jersey District Court) entered a stipulation and order dismissing without prejudice Sandoz GmbH, Lek Pharmaceuticals d.d., Novartis Pharmaceutical Productions d.o.o. and Novartis AG (collectively \u201cForeign Defendants\u201d) from the action. Pursuant to the stipulation entered by the New Jersey District Court, the Foreign Defendants agre"
    },
    {
      "competitor": "ANALYSIS OF FINANCIAL CONDITION",
      "mentions": 1,
      "context": "petition and Innovation Act (BPCIA) Litigation Amgen Inc. et al. v. Sandoz Inc., et al. On August 23, 2023, the U.S. District Court for the District of New Jersey (New Jersey District Court) entered a stipulation and order dismissing without prejudice Sandoz GmbH, Lek Pharmaceuticals d.d., Novartis Pharmaceutical Productions d.o.o. and Novartis AG (collectively \u201cForeign Defendants\u201d) from the action. Pursuant to the stipulation entered by the New Jersey District Court, the Foreign Defendants agre"
    },
    {
      "competitor": "MD&A",
      "mentions": 3,
      "context": "petition and Innovation Act (BPCIA) Litigation Amgen Inc. et al. v. Sandoz Inc., et al. On August 23, 2023, the U.S. District Court for the District of New Jersey (New Jersey District Court) entered a stipulation and order dismissing without prejudice Sandoz GmbH, Lek Pharmaceuticals d.d., Novartis Pharmaceutical Productions d.o.o. and Novartis AG (collectively \u201cForeign Defendants\u201d) from the action. Pursuant to the stipulation entered by the New Jersey District Court, the Foreign Defendants agre"
    },
    {
      "competitor": "SEC",
      "mentions": 1,
      "context": "petition and Innovation Act (BPCIA) Litigation Amgen Inc. et al. v. Sandoz Inc., et al. On August 23, 2023, the U.S. District Court for the District of New Jersey (New Jersey District Court) entered a stipulation and order dismissing without prejudice Sandoz GmbH, Lek Pharmaceuticals d.d., Novartis Pharmaceutical Productions d.o.o. and Novartis AG (collectively \u201cForeign Defendants\u201d) from the action. Pursuant to the stipulation entered by the New Jersey District Court, the Foreign Defendants agre"
    },
    {
      "competitor": "EPS",
      "mentions": 1,
      "context": "petition and Innovation Act (BPCIA) Litigation Amgen Inc. et al. v. Sandoz Inc., et al. On August 23, 2023, the U.S. District Court for the District of New Jersey (New Jersey District Court) entered a stipulation and order dismissing without prejudice Sandoz GmbH, Lek Pharmaceuticals d.d., Novartis Pharmaceutical Productions d.o.o. and Novartis AG (collectively \u201cForeign Defendants\u201d) from the action. Pursuant to the stipulation entered by the New Jersey District Court, the Foreign Defendants agre"
    }
  ]
}